JP2024541770A - 神経障害の治療方法 - Google Patents

神経障害の治療方法 Download PDF

Info

Publication number
JP2024541770A
JP2024541770A JP2024531094A JP2024531094A JP2024541770A JP 2024541770 A JP2024541770 A JP 2024541770A JP 2024531094 A JP2024531094 A JP 2024531094A JP 2024531094 A JP2024531094 A JP 2024531094A JP 2024541770 A JP2024541770 A JP 2024541770A
Authority
JP
Japan
Prior art keywords
compound
administered
fesoterodine
pharma
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024531094A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024541770A5 (https=
JPWO2023097276A5 (https=
Inventor
リリー，ジェームズ
ウッド，マイケル
Original Assignee
マップライト セラピューティクス，インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マップライト セラピューティクス，インコーポレイテッド filed Critical マップライト セラピューティクス，インコーポレイテッド
Publication of JP2024541770A publication Critical patent/JP2024541770A/ja
Publication of JP2024541770A5 publication Critical patent/JP2024541770A5/ja
Publication of JPWO2023097276A5 publication Critical patent/JPWO2023097276A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4245—Oxadiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A61K31/24—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group having an amino or nitro group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2024531094A 2021-11-24 2022-11-23 神経障害の治療方法 Pending JP2024541770A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202163283140P 2021-11-24 2021-11-24
US63/283,140 2021-11-24
US202263416745P 2022-10-17 2022-10-17
US63/416,745 2022-10-17
PCT/US2022/080429 WO2023097276A1 (en) 2021-11-24 2022-11-23 Methods of treating neurological disorders

Publications (3)

Publication Number Publication Date
JP2024541770A true JP2024541770A (ja) 2024-11-12
JP2024541770A5 JP2024541770A5 (https=) 2025-07-16
JPWO2023097276A5 JPWO2023097276A5 (https=) 2025-07-16

Family

ID=86540399

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024531094A Pending JP2024541770A (ja) 2021-11-24 2022-11-23 神経障害の治療方法

Country Status (9)

Country Link
US (1) US20250032460A1 (https=)
EP (1) EP4436564A4 (https=)
JP (1) JP2024541770A (https=)
KR (1) KR20240110642A (https=)
AU (1) AU2022396530A1 (https=)
CA (1) CA3239067A1 (https=)
IL (1) IL313067A (https=)
MX (1) MX2024006371A (https=)
WO (1) WO2023097276A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3061821T (pt) * 2009-07-22 2019-09-05 PureTech Health LLC Composições para tratamento de distúrbios melhorados por ativação de recetores muscarínicos
US8853219B2 (en) * 2010-01-11 2014-10-07 Neurosolis, Inc. Compounds and compositions for cognition-enhancement, methods of making, and methods of treating
WO2012033956A1 (en) * 2010-09-08 2012-03-15 Mithridion, Inc. Cognition enhancing compounds and compositions, methods of making, and methods of treating
US9012489B2 (en) * 2011-08-03 2015-04-21 Boehringer Ingelheim International Gmbh Phenyl-3-aza-bicyclo[3.1.0]hex-3-yl-methanones and the use thereof as medicament
CA2978214A1 (en) * 2015-03-06 2016-09-15 Chase Pharmaceuticals Corporation Peripheral-anticholinergic muscarinic agonist combination

Also Published As

Publication number Publication date
CA3239067A1 (en) 2023-06-01
US20250032460A1 (en) 2025-01-30
EP4436564A4 (en) 2025-10-22
EP4436564A1 (en) 2024-10-02
IL313067A (en) 2024-07-01
MX2024006371A (es) 2024-07-15
AU2022396530A1 (en) 2024-06-13
KR20240110642A (ko) 2024-07-15
WO2023097276A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US10912744B2 (en) Therapeutic formulation for reduced drug side effects
US20170196872A1 (en) Methods of treating patients suffering from movement disorders
JP2002511409A (ja) 神経精神疾患の治療法
US20170105983A1 (en) Compositions for reduction of side effects
AU2024202516A1 (en) Pharmaceutical combination and its use for treating synucleinopathies
EP2968227B1 (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis
TWI803488B (zh) Nk-1拮抗劑組合及治療突觸核蛋白病症之方法
JP2024541770A (ja) 神経障害の治療方法
CN118510500A (zh) 治疗神经系统障碍的方法
JP7709202B2 (ja) 睡眠障害を伴うｃｎｓ障害の治療
US5948806A (en) Treatment of Parkinson's disease with (+)2-(ethyl-2,3-dihydrobenzofuranyl)-2-Imidazoline (dexefaroxan or (+) efaroxan)
JP2020514347A (ja) チオトロピウムを有効成分として含有する近視予防、近視治療および／または近視進行抑制剤
CN121443286A (zh) 用于治疗神经障碍的组合物
CN116194092A (zh) 经口给予制剂
US20230028539A1 (en) Pharmaceutical composition, complementary kit and application thereof
WO2025143100A1 (ja) 神経変性疾患治療剤
CA3096453C (en) Pharmaceutical combination comprising fluoxetine and pramipexole and its use for treating synucleinopathies
EP4648797A1 (en) Use of (s)-3-amino-4-(difluoromethylenyl) cyclopent-1-ene-1-carboxylic acid in the treatment of multiple sclerosis
HK40017808A (en) Methods of treating seizure disorders
HK1220609B (en) S-enantiomerically enriched compositions of beta blockers for treating amyotrophic lateral sclerosis

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251118